Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.47 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 7/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.40 |
| ▸ | TPSD1 | Q9BZJ3 | 3/20 | 0.40 |
| ▸ | TPSG1 | Q9NRR2 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5640985 | 0.82 | F2 (0.56) | F10F2PRSS1CASP3ACE | |
| SCHEMBL3724402 | 0.82 | F2 (0.56) | F10F2PRSS1CASP3ACE | |
| SCHEMBL12527914 | 0.81 | KMT2A (0.55) | F10F2PRSS1CASP3ACE | |
| SCHEMBL12527916 | 0.81 | KMT2A (0.54) | F10F2PRSS1CASP3ACE | |
| SCHEMBL4984560 | 0.80 | CASP3 (0.59) | F10F2PRSS1CASP3ACE | |
| SCHEMBL4984571 | 0.80 | CASP3 (0.59) | F10F2PRSS1CASP3ACE | |
| SCHEMBL12494289 | 0.79 | MMP1 (0.55) | F10F2PRSS1CASP3ACE | |
| SCHEMBL12525646 | 0.79 | MMP1 (0.55) | F10F2PRSS1CASP3ACE | |
| SCHEMBL9608921 | 0.79 | F10 (0.60) | F10F2PRSS1CASP3ACE | |
| SCHEMBL203869 | 0.79 | F2 (0.59) | F10F2PRSS1CASP3ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385080-B2 | STAT6 inhibitors | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180222931-A1 | STAT6 INHIBITORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180222931-A1 | STAT6 INHIBITORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-08-09 | — | — | US | disclosed |
| US-9765099-B2 | STAT6 inhibitors | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765099-B2 | STAT6 inhibitors | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160145279-A1 | STAT6 INHIBITORS | BAYLOR COLLEGE OF MEDICINE (US) | 2016-05-26 | — | — | US | disclosed |
| US-20160145279-A1 | STAT6 INHIBITORS | BAYLOR COLLEGE OF MEDICINE (US) | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385080-B2 | STAT6 inhibitors | STAT6, STAT3, STAT1 | F10 4304/4885F2 3495/4885PRSS1 1859/4885 |
| US-20160145279-A1 | STAT6 INHIBITORS | STAT6, STAT3, STAT1 | F10 4304/4885F2 3495/4885PRSS1 1859/4885 |
| US-20180222931-A1 | STAT6 INHIBITORS | STAT6, STAT3, STAT1 | F10 4304/4885F2 3495/4885PRSS1 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.